Institute of Psychiatry, Psychology and Neuroscience

Leading child mental health organisations call for global action against infant, child and adolescent trauma

Retrieved on: 
Thursday, June 1, 2023
Learning, SCAP, American Academy of Child and Adolescent Psychiatry, Society, Child and adolescent psychiatry, International Association for Child and Adolescent Psychiatry and Allied Professions, Disability, AACAP, Supervised visitation, Mental health, Institute of Psychiatry, Psychology and Neuroscience, International Association, American Academy, Adverse childhood experiences, King's College London, Academy of Medicine, DSM-IV codes, Bentham Science Publishers, National Children's Mental Health Awareness Week, ASCAP, Royal Australian and New Zealand College of Psychiatrists, ACeS, Journal of Indian Association for Child and Adolescent Mental Health, International Society, Growth, Trauma, IACAPAP, Infant, Adolescence, Nursing, Birth control, Toy, Psychology, Neuroscience, Psychotherapy, Child, Psychiatry, Research

To address this pressing concern and mobilise global efforts, the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP), International Society for Adolescent Psychiatry and Psychology (ISAPP), World Association for Infant Mental Health (WAIMH), and World Psychiatric Association Child and Adolescent Psychiatry (WPA-CAP) have jointly declared April 23 as the World Infant, Child and Adolescent Mental Health Day (WICAMHD).

Key Points: 
  • To address this pressing concern and mobilise global efforts, the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP), International Society for Adolescent Psychiatry and Psychology (ISAPP), World Association for Infant Mental Health (WAIMH), and World Psychiatric Association Child and Adolescent Psychiatry (WPA-CAP) have jointly declared April 23 as the World Infant, Child and Adolescent Mental Health Day (WICAMHD).
  • This year witnessed the second annual WICAMHD event under the theme of Stand Against Infant, Child and Adolescent Trauma.
  • Dr Dennis Ougrin, Consultant Child and Adolescent Psychiatrist, Visiting Professor of Child and Adolescent Psychiatry and Global Mental Health, Institute of Psychiatry, Psychology and Neuroscience, King's College London discussed the impacts of the war in Ukraine.
  • These include the Indian Association for Child and Adolescent Mental Health (IACAM), the Lithuanian Society of Child and Adolescent Psychiatry (LVPPD), the American Academy of Child and Adolescent Psychiatry (AACAP), the Austrian Society of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy (ASCAP) and the Section of Child and Adolescent Psychiatry, College of Psychiatrists, Academy of Medicine, Singapore (SCAP).

Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer

Retrieved on: 
Monday, January 9, 2023
Agitation, Migraine, Central nervous system, Food, MDD, Therapy, Bipolar disorder, CORAL, Institute of Psychiatry, Psychology and Neuroscience, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Business, Pfizer, National University of Ireland, Alzheimer's disease, New York University Grossman School of Medicine, MBA, Narcolepsy, CNS, National university, Medical Affairs Bureau, New York University Stern School of Business, Schizophrenia, Cognition, Psychiatry, Senior, Pharmaceutical industry, Medical device

CORAL GABLES, Fla., Jan. 9, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Cedric O'Gorman MD as the Company's Chief Medical Officer.

Key Points: 
  • CORAL GABLES, Fla., Jan. 9, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Cedric O'Gorman MD as the Company's Chief Medical Officer.
  • Dr. O'Gorman brings to Relmada more than two decades of life sciences experience in clinical development, medical affairs and medical strategy, with significant expertise in the CNS therapeutics field.
  • Most recently, he served as Chief Medical Officer at Alpha Cognition, where he led clinical development programs for the company's Alzheimer's disease targets.
  • "Dr. O'Gorman adds important depth to our management team given his extensive CNS medical and research experience, and his demonstrated leadership acumen," stated Sergio Traversa, Relmada's Chief Executive Officer.

COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Thursday, November 3, 2022
G&A, Company, Research, TRD, Psilocybin, Food, Institute, King's College London, Autism, FDA, Investor, Mount Sinai Hospital, Webcast, Columbia University Irving Medical Center, Psychology, COMP, University, University College London Hospitals NHS Foundation Trust, Nasdaq, South London and Maudsley NHS Foundation Trust, Post-traumatic stress disorder, Mental health, Capital market, US Foods, Digital, MT, Clinical trial, Depression, Pivotal, The New England Journal of Medicine, CMPS, Program, R, ASD, COMPASS, Institute of Psychiatry, Psychology and Neuroscience, UC San Diego School of Medicine, PTSD, Patient, Anorexia nervosa, Pharmaceutical industry, Life insurance, Cryptocurrency

Research and development (R&D) expenses were $14.0 million for the three months ended 30 September 2022, compared with $12.2 million during the same period in 2021.

Key Points: 
  • Research and development (R&D) expenses were $14.0 million for the three months ended 30 September 2022, compared with $12.2 million during the same period in 2021.
  • The COMPASS Pathways management team will host a conference call at 8.00am ET (12.00pm UK) on 3 November 2022.
  • A live webcast of the call will be available on COMPASS Pathways website at: Third Quarter 2022 Financial Results .
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.

COMPASS Pathways plc announces second quarter 2022 financial results and business highlights

Retrieved on: 
Thursday, August 4, 2022
Phase II, Post-traumatic stress disorder, CMPS, Goldsmith, TRD, Senior, Innovation, ASD, Clinical trial, Mental Health Research Institute (Melbourne), COMPASS, Autism, III, Investor, Columbia University Irving Medical Center, Patient, Food, Mental health, Review, II, IIB, Nasdaq, FDA, University College London Hospitals NHS Foundation Trust, Mount Sinai Hospital, Policy, Institute, South London and Maudsley NHS Foundation Trust, Research, Institute of Psychiatry, Psychology and Neuroscience, US Foods, Otsuka Pharmaceutical, Sheppard and Enoch Pratt Hospital, Anorexia nervosa, Psilocybin, Principal investigator, Slam, R, CEO, KOL, PTSD, Webcast, G&A, UC San Diego School of Medicine, Leadership, Psychology, University, Center, Partnership, King's College London, Pharmaceutical industry, Online gambling, Video game

COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2022 and gave an update on recent progress across its business.

Key Points: 
  • COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2022 and gave an update on recent progress across its business.
  • The COMPASS Pathways management team will host a conference call at 8.00am ET (13.00 UK) on 4 August 2022.
  • A live webcast of the call will be available on COMPASS Pathways website at: Second Quarter 2022 Financial Results .
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.

COMPASS Pathways plc announces first quarter 2022 financial results and business highlights

Retrieved on: 
Tuesday, May 10, 2022
ASD, Psilocybin, Society, Autism, Nasdaq, Post-traumatic stress disorder, CMPS, Biological Psychiatry (journal), IIB, Food, Psychology, South London and Maudsley NHS Foundation Trust, COMPASS, Clinical trial, Anorexia nervosa, FDA, Center, III, Institute of Psychiatry, Psychology and Neuroscience, Institute, Mental Health Research Institute (Melbourne), US Foods, PTSD, SSRI, TRD, Mental health, CEO, G&A, Pharmaceutical industry

George Goldsmith, Chairman, CEO and Co-founder, COMPASS Pathways, said, COMPASS made great progress this quarter including a productive end-of-phase II FDA meeting and we are actively working to finalise our phase III programme.

Key Points: 
  • George Goldsmith, Chairman, CEO and Co-founder, COMPASS Pathways, said, COMPASS made great progress this quarter including a productive end-of-phase II FDA meeting and we are actively working to finalise our phase III programme.
  • R&D expenses were $15.4 million for the three months ended 31 March 2022, compared with $6.9 million during the same period in 2021.
  • The COMPASS Pathways management team will host a conference call at 1.00pm UK (8.00am ET) on 10 May 2022.
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.

COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults

Retrieved on: 
Monday, May 9, 2022
Psilocybin, University, Autism Research Centre, Nasdaq, Autism, CMPS, IIB, Tobias, Food, Research, Translational neuroscience, Doctor of Philosophy, South London and Maudsley NHS Foundation Trust, Psychology, Clinical trial, FDA, Institute of Psychiatry, Psychology and Neuroscience, Institute, US Food Sovereignty Alliance, Adult, TRD, Mental health, Pharmaceutical industry, Medical imaging

COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it will be funding an investigator-initiated study that will use COMP360 psilocybin to explore how psilocybin affects specific brain pathways in autistic adults.

Key Points: 
  • COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it will be funding an investigator-initiated study that will use COMP360 psilocybin to explore how psilocybin affects specific brain pathways in autistic adults.
  • This will be the first ever mechanistic study of psilocybin in autistic adults.
  • Professor Grainne McAlonan, IoPPN, said: I am delighted that COMPASS Pathways is supporting our investigations into the brain science of neurodiversity.
  • Dr Guy Goodwin, Chief Medical Officer, COMPASS Pathways, said: We are pleased to fund this innovative research, the first of its kind using psilocybin in autistic adults.

COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK

Retrieved on: 
Thursday, March 24, 2022
COMPASS, NHS, Anorexia nervosa, Mental health, IIB, Post-traumatic stress disorder, Bethlem Royal Hospital, Growth, Clinical trial, PTSD, South London and Maudsley NHS Foundation Trust, Research, CMPS, Certification, Government, Institute of Psychiatry, Psychology and Neuroscience, CEO, Food, Maudsley Hospital, Health, Center, Mental Health Research Institute (Melbourne), TRD, US Foods, Institute, Nasdaq, FDA, Slam, Psychology, Patient, Partnership, Medicine, Pharmaceutical industry

COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has formed a long-term strategic partnership to launch The Centre for Mental Health Research and Innovation (the Centre) to accelerate psychedelic research and develop new models of care for mental health in the UK.

Key Points: 
  • COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has formed a long-term strategic partnership to launch The Centre for Mental Health Research and Innovation (the Centre) to accelerate psychedelic research and develop new models of care for mental health in the UK.
  • We are grateful to be able to play a part in this, and to be working with SLaM and the IoPPN, UK leaders in patient care and research in mental health.
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.
  • The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at Kings is the premier centre for mental health and related neurosciences research in Europe.

Vancouver discovery will make ‘Magic Mushroom’ mental health care cheaper

Retrieved on: 
Wednesday, February 23, 2022
Psilocybin, GLOBE, Depression, PTSD, SAP, Government, McMillan LLP, Institute of Psychiatry, Psychology and Neuroscience, Lists of diseases, University, Research, Special access program, Mental health, UBC, DNA, University of British Columbia, Bacteria, McMillan, Opioid, Neurodegeneration, Institute, Health Canada, Anxiety, Johns Hopkins University, Pacific Northwest, Patent, Canada Research Chair, Engineering, Legislation, Nanos Research, Pharmaceutical industry, Medicine, Psychology, BC, Genomics, Health

Vancouver, BC, Feb. 23, 2022 (GLOBE NEWSWIRE) -- A team of Vancouver scientists has discovered a new process to cost-effectively make psilocybin, the active ingredient in magic mushrooms, paving the way for greater and more affordable treatments for a range of addictions and mental health conditions.

Key Points: 
  • Vancouver, BC, Feb. 23, 2022 (GLOBE NEWSWIRE) -- A team of Vancouver scientists has discovered a new process to cost-effectively make psilocybin, the active ingredient in magic mushrooms, paving the way for greater and more affordable treatments for a range of addictions and mental health conditions.
  • Recent research has found psilocybin is effective in the treatment of alcohol and opiate addiction, PTSD, depression, and anxiety.
  • The breakthrough discovery comes in the wake of Health Canada approving the Special Access Program (SAP) use of psilocybin in psychedelic assisted therapy for mental illness, which afflicts 1 in 5 people inCanada every year.
  • The science and engineering by our scientists is playing a significant role in furthering mental health research with cost-effective psychedelic compounds, he said.

COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology

Retrieved on: 
Tuesday, January 4, 2022
Safety, Emotion, South London and Maudsley NHS Foundation Trust, US Foods, Volunteering, SSRI, TRD, Institute, Institute of Psychiatry, Psychology and Neuroscience, Clinical trial, Psychology, FDA, DOI, PTSD, Journal of Psychopharmacology, III, CMPS, Female, Food, IIB, Psilocybin, Mental health, Male, Adult, Patient, Nasdaq, Journal, Thought, Pharmaceutical industry, Psychopharmacology, South London

The study looked at the effects of two doses of COMP360 psilocybin (10mg and 25mg), compared with placebo, in 89 healthy male and female adult volunteers.

Key Points: 
  • The study looked at the effects of two doses of COMP360 psilocybin (10mg and 25mg), compared with placebo, in 89 healthy male and female adult volunteers.
  • The participants were randomised in a 1:1:1 ratio to receive 10mg COMP360 (n=30), 25mg COMP360 (n=30), or placebo (n=29).
  • There were no serious adverse events and COMP360 psilocybin was found to be well-tolerated with no clinically-relevant negative effects on cognitive function.
  • Dr Guy Goodwin, Chief Medical Officer, COMPASS Pathways, said: This study was an early part of our clinical development programme for COMP360 psilocybin therapy.

COMPASS Pathways plc announces financial results and business highlights for the third quarter 2021

Retrieved on: 
Tuesday, November 9, 2021
IIB, Psychology, Safety, PTSD, Cancer, G&A, Private Securities Litigation Reform Act, COMPASS, III, R, Depression, TRD, CEO, Terminology, Research and development, U.S. Securities and Exchange Commission, Food, US Foods, Goal, Research, Social media, Securities Act of 1933, Forward-looking statement, Hematology, Intention, IP, File, Annual report, Mental health, GLOBE, LinkedIn, The Institute, CMPS, SEC, Review, Institute of Psychiatry, Psychology and Neuroscience, Nasdaq, Patient, FDA, Pharmaceutical industry

Research & development (R&D) expenses were $12.2 million for the three months ended 30 September 2021, compared with $6.9 million during the same period in 2020.

Key Points: 
  • Research & development (R&D) expenses were $12.2 million for the three months ended 30 September 2021, compared with $6.9 million during the same period in 2020.
  • The COMPASS Pathways management team will host a conference call at 1.00pm UK (8.00am ET) on 9 November 2021.
  • The call will be accompanied by a presentation which will be available on the COMPASS Pathways website (ir.compasspathways.com).
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.